Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers

Xintela has today received approval from the Medical Products Agency for a clinical Phase I/IIa study with XSTEM in patients with difficult-to-heal venous leg ulcers. XSTEM consists of integrin α10β1-selected and quality-assured mesenchymal stem cells and is produced in Xintela's own GMP facility.

In the clinical study, which will be carried out in collaboration with Professor Folke Sjöberg and his team at the University Hospital in Linköping, 12 patients with difficult-to-heal venous leg ulcers will be treated with XSTEM or placebo. XSTEM/placebo will be applied onto the wounds and the patients will be followed for 10 weeks to evaluate safety and wound healing effect. The study will start after the summer and early results are expected by the end of 2022.

Difficult-to-heal venous leg ulcers, which affect about 4% of people over the age of 65, result in pain and reduced quality of life for patients as well as large costs for the healthcare system. There is currently no effective cure for this indication.

“We are really pleased with the approval from the Medical Products Agency so that we can start our clinical study in patients with difficult-to-heal venous leg ulcers according to plan. We now have the opportunity to generate clinical data with XSTEM within a short time and in a patient group where the medical need is huge. Our preclinical studies have shown that XSTEM has excellent wound healing capacity and has the potential to become a pioneering treatment for difficult-to-heal leg ulcers,” says Camilla Wennersten, Director Clinical Development.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

This information is information that Xintela AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-07-05 14:55 CEST.

Attachments

Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers